The DeSci Podcast
The Decentralized Biotech Movement with Dr. Jocelynn Pearl (LabDAO)
Sep 20, 2023
Dr. Jocelynn Pearl, biotech scientist and co-founder of LabDAO, discusses the birth of Decentralized Biotech, the importance of incentivizing knowledge sharing, pros and cons of centralization in Biotech, limits of online collaboration, sharing tacit knowledge, funding for good projects, and contentious topics within LabDAO.
41:36
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Decentralized biotech aims to break silos and incentivize knowledge sharing for global drug development.
- Centralized biotech companies lack effective mechanisms to incentivize sharing of tacit knowledge and expertise.
Deep dives
The Drawbacks of Centralization in Biotech
Decentralized biotech has emerged as a movement driven by individuals interested in collective global drug development. The focus is on breaking the traditional silos and ivory towers of academia and biotech companies, where scientific knowledge is often not shared. The idea is to incentivize knowledge sharing and collaboration within an online community. Centralization in biotech poses challenges, such as limited access to knowledge and lack of transparency and sharing within companies. The decentralized approach aims to disrupt the traditional system and create new ways of advancing drug development through open science and incentivization mechanisms.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
